Thomson Reuters Awarded Grant from The Michael J. Fox Foundation to Provide Most Complete Source of LRRK2-Protein Biological Maps for Parkinson's Disease
(Thomson Reuters ONE) -
Thomson Reuters MetaCore suite instrumental in helping researchers find
disease's cure
Philadelphia, PA, London, UK, December 1, 2011 - Thomson Reuters, the world's
leading source of intelligent information for businesses and professionals and
the global leader in scientific information, announced today a grant from The
Michael J. Fox Foundation for Parkinson's Research (MJFF) to create and publish
the world's most comprehensive source of biological maps for Parkinson's disease
(PD).
The project aims to identify possible causes of Parkinson's disease by mapping
biological mutations of the Leucine-rich repeat kinase 2 (LRRK2) protein, the
most common genetic contributor to the disease discovered to date. The maps
trace the disease's biological pathways to pinpoint relevant biomarkers, which
are biological molecules that signal an abnormal process or disease. They also
support the drug discovery process for treating PD.
"Researching the LRRK2 protein is a top priority for our foundation," said Brian
Fiske, Ph.D., director of research programs at MJFF. "We are committed to
providing valuable tools, such as those from Thomson Reuters, for the research
community to visually depict LRRK2 research data in useful and comprehensible
formats."
Thomson Reuters creates biological maps using the highest quality scientific
literature data that is manually annotated using the business's proprietary
curation methods. The data selected for the maps is evaluated based on select
criteria to ensure exceptional depth, breadth and quality of information for the
researchers using it.
"The pathway maps and unique content Thomson Reuters is developing for the MJFF
project are especially valuable in shedding light on Parkinson's disease and its
cause," said Jon Brett-Harris, executive vice president, Life Sciences, Thomson
Reuters. "The maps will provide PD researchers with a resource to reveal the
mechanisms behind the disease and further extend the drug discovery process. We
are honoured to have the opportunity to work with the MJFF on this critical
program."
Users of the Thomson Reuters MetaCore offering, an integrated software suite
delivering high-quality biological systems, will be able to access the pathway
maps for greater insight via MetaCore's analysis tools.
For more information about pathway analysis tools at Thomson Reuters, please
visit http://thomsonreuters.com/products_services/science/science_products/a-
z/metacore/.
About The Michael J. Fox Foundation for Parkinson's Research
As the world's largest private funder of Parkinson's research, The Michael J.
Fox Foundation is dedicated to accelerating a cure for Parkinson's disease and
improved therapies for those living with the condition today. The Foundation
pursues its goals through an aggressively funded, highly targeted research
program coupled with active global engagement of scientists, Parkinson's
patients, business leaders, clinical trial participants, donors and volunteers.
In addition to funding more than $270 million in research to date, the
Foundation has fundamentally altered the trajectory of progress toward a cure.
Operating at the hub of worldwide Parkinson's research, the Foundation forges
groundbreaking collaborations with industry leaders, academic scientists and
government research funders; increases the flow of participants into Parkinson's
disease clinical trials with its online tool, Fox Trial Finder; promotes
Parkinson's awareness through high-profile advocacy, events and outreach; and
coordinates the grassroots involvement of thousands of Team Fox members around
the world. Now through December 31, 2012, all new and increased giving to The
Michael J. Fox Foundation, as well as gifts from donors who have not given since
2009 or earlier, will be matched on a dollar-for-dollar basis with the $50-
million Brin Wojcicki Challenge, launched by Sergey Brin and Anne Wojcicki. For
more information, visit:www.michaeljfox.org.
Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial, legal, tax and accounting, healthcare and science and media markets,
powered by the world's most trusted news organization. With headquarters in New
York and major operations in London and Eagan, Minnesota, Thomson Reuters
employs more than 55,000 people and operates in over 100 countries. For more
information, go towww.thomsonreuters.com.
CONTACT
Alyssa Velekei
Thomson Reuters
+1 215 823 1894
alyssa.velekei(at)thomsonreuters.com
Laura Gaze
Thomson Reuters
+1 203 868 3340
laura.gaze(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1568332]
Unternehmensinformation / Kurzprofil:
Datum: 01.12.2011 - 19:32 Uhr
Sprache: Deutsch
News-ID 93262
Anzahl Zeichen: 5907
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 173 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Awarded Grant from The Michael J. Fox Foundation to Provide Most Complete Source of LRRK2-Protein Biological Maps for Parkinson's Disease"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
